Chalmé Rebecca L, Rubin Eric, Evans Suzette M, Haney Margaret, Foltin Richard W
Division on Substance Use Disorders, New York State Psychiatric Institute and Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Division on Substance Use Disorders, New York State Psychiatric Institute and Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Pharmacol Biochem Behav. 2025 Feb;247:173918. doi: 10.1016/j.pbb.2024.173918. Epub 2024 Nov 29.
Individuals seeking treatment for their cocaine use often report depressive systems and nearly half meet criteria for major depressive disorder (MDD). This descriptive study aimed to assess the effects of the antidepressant venlafaxine alone and in combination with gabapentin on depressive symptoms, subjective effects of cocaine, and cocaine self-administration in depressed and non-depressed people who use cocaine. The effects of medication condition on mood and on the effects of smoked cocaine were compared between a group of clinically depressed people who use cocaine (n = 5) and a control group of non-depressed people who use cocaine (n = 5) using laboratory-based measures. In the MDD group, venlafaxine (300 mg/day) was associated with reduced mean Beck Depression Inventory (BDI) scores (35 to <5) and marginally lower ratings of "good drug effect" without affecting cocaine "wanting" or cocaine (0-50 mg) self-administration. In both groups, venlafaxine treatment increased resting heart rate, systolic pressure, and diastolic pressure. The addition of gabapentin (2400 mg/day) had no effect relative to venlafaxine alone for either group. Conclusions regarding venlafaxine's effectiveness in treating depression in the MDD group are tempered by the lack of a venlafaxine placebo condition and by reductions in BDI scores associated with abstinence prior to venlafaxine administration. Further research is necessary to identify effective treatments for depressed people who use cocaine.
寻求治疗可卡因使用问题的个体经常报告有抑郁症状,近半数符合重度抑郁症(MDD)的标准。这项描述性研究旨在评估抗抑郁药文拉法辛单独使用以及与加巴喷丁联合使用,对使用可卡因的抑郁和非抑郁人群的抑郁症状、可卡因主观效应及可卡因自我给药的影响。使用基于实验室的测量方法,比较了一组使用可卡因的临床抑郁症患者(n = 5)和一组使用可卡因的非抑郁症对照组(n = 5)中药物治疗情况对情绪及吸食可卡因效果的影响。在MDD组中,文拉法辛(300毫克/天)与平均贝克抑郁量表(BDI)评分降低(从35降至<5)以及“良好药物效果”评分略有降低相关,且不影响对可卡因的“渴望”或可卡因(0 - 50毫克)的自我给药。在两组中,文拉法辛治疗均使静息心率、收缩压和舒张压升高。加用加巴喷丁(2400毫克/天)相对于单独使用文拉法辛对两组均无影响。由于缺乏文拉法辛安慰剂对照条件以及在文拉法辛给药前与戒断相关的BDI评分降低,关于文拉法辛在MDD组治疗抑郁症有效性的结论受到影响。有必要进行进一步研究以确定针对使用可卡因的抑郁症患者的有效治疗方法。